BridgeMD
Remimazolam versus propofol for deep sedation during Endoscopic Ultrasound (EUS) procedures. A randomized controlled trial.
EU CTIS ID: 2025-521784-12-00
What this study is testing
To compare a remimazolam-based sedation regimen managed by endoscopists to a propofol-based sedation regimen performed by anesthesiologists during EUS gastrointestinal procedures.
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Patients >18 years
- Patients scheduled for elective EUS gastrointestinal procedures
- Signed informed consent
- Outpatient procedures
You likely can't join if
- Patients < 18 years
- Patients scheduled for urgent EUS gastrointestinal procedures
- Known contraindications to the use of propofol and/or remimazolam
- Patient’s refusal to participate
- Procedures that require orotracheal intubation
- Pregnant and breastfeeding women
See the full eligibility criteria
- Patients >18 years
- Patients scheduled for elective EUS gastrointestinal procedures
- Signed informed consent
- Outpatient procedures
- Patients < 18 years
- Patients scheduled for urgent EUS gastrointestinal procedures
- Known contraindications to the use of propofol and/or remimazolam
- Patient’s refusal to participate
- Procedures that require orotracheal intubation
- Pregnant and breastfeeding women
- Inpatient procedures
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.